Targeting mitochondria: A new promising approach for the treatment of liver diseases

Current Medicinal Chemistry

Volumn 17, Issue 22, 2010, Pages 2325-2337

  Serviddio, G ^a   Bellanti, F ^a   Sastre, J ^b   Vendemiale, G ^c   Altomare, E ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF VALENCIA   (Spain)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Mitochondria; mitochondria targeted therapy; NAFLD; Oxidative stress; Uncoupling

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIOXIDANT; LIPOSOME; PEPTIDE DERIVATIVE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; XJB 5131;

AEROBIC METABOLISM; APOPTOSIS; ARTICLE; BIOENERGY; CELL DEATH; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; LIVER CELL; LIVER DISEASE; MEMBRANE PERMEABILITY; MITOCHONDRION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE PHOSPHORYLATION UNCOUPLING; OXIDATIVE STRESS; PATHOGENESIS;

ANIMALS; CELL DEATH; DRUG DELIVERY SYSTEMS; HUMANS; LIVER DISEASES; MITOCHONDRIA; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 77955650026     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710791698530     Document Type: Article

References (172)

1. Khan, S. A.; Shah, N.; Williams, R.; Jalan, R. Acute liver failure: a review. Clin. Liver Dis., 2006, 10, 239-viii.
2. Bell, B. P.; Manos, M. M.; Zaman, A.; Terrault, N.; Thomas, A.; Navarro, V. J.; Dhotre, K. B.; Murphy, R. C.; Van Ness, G. R.; Stabach, N.; Robert, M. E.; Bower, W. A.; Bialek, S. R.; Sofair, A. N. The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance. Am. J. Gastroenterol., 2008, 103, 2727-2736.
3. Chun, L. J.; Tong, M. J.; Busuttil, R. W.; Hiatt, J. R. Acetaminophen hepatotoxicity and acute liver failure. J. Clin. Gastroenterol., 2009, 43, 342-349.
4. Shepard, C. W.; Finelli, L.; Alter, M. J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis., 2005, 5, 558-567.
5. O'Shea, R. S.; Dasarathy, S.; McCullough, A. J. Alcoholic liver disease. Hepatology, 2010, 51, 307-328.
6. Serviddio, G.; Sastre, J.; Bellanti, F.; Vina, J.; Vendemiale, G.; Altomare, E. Mitochondrial involvement in non-alcoholic steatohepatitis. Mol. Aspects Med., 2008, 29, 22-35.
7. Malhi, H.; Gores, G. J. Cellular and molecular mechanisms of liver injury. Gastroenterology, 2008, 134, 1641-1654.
8. Malhi, H.; Gores, G. J.; Lemasters, J. J. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology, 2006, 43, S31-S44.
9. Forner, F.; Foster, L. J.; Campanaro, S.; Valle, G.; Mann, M. Quantitative proteomic comparison of rat mitochondria from muscle, heart, and liver. Mol. Cell Proteomics., 2006, 5, 608-619.
10. Sastre, J.; Serviddio, G.; Pereda, J.; Minana, J. B.; Arduini, A.; Vendemiale, G.; Poli, G.; Pallardo, F. V.; Vina, J. Mitochondrial function in liver disease. Front Biosci., 2007, 12, 1200-1209.
11. Wallace, D. C.; Singh, G.; Lott, M. T.; Hodge, J. A.; Schurr, T. G.; Lezza, A. M.; Elsas, L. J.; Nikoskelainen, E. K. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science, 1988, 242, 1427-1430.
12. Liu, X.; Kim, C. N.; Yang, J.; Jemmerson, R.; Wang, X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell, 1996, 86, 147-157.
13. Armstrong, J. S. Mitochondrial medicine: pharmacological targeting of mitochondria in disease. Br. J. Pharmacol., 2007, 151, 1154-1165.
14. Pathak, A.; Vyas, S. P.; Gupta, K. C. Nano-vectors for efficient liver specific gene transfer. Int. J. Nanomed., 2008, 3, 31-49.
15. Frey, T. G.; Mannella, C. A. The internal structure of mitochondria. Trends Biochem. Sci., 2000, 25, 319-324.
16. Endo, T.; Yamano, K. Transport of proteins across or into the mitochondrial outer membrane. Biochim. Biophys. Acta, 2009,
17. Mannella, C. A. Structure and dynamics of the mitochondrial inner membrane cristae. Biochim. Biophys. Acta, 2006, 1763, 542-548.
18. Srere, P. A. Citric acid cycle redux. Trends Biochem. Sci., 1990, 15, 411-412.
19. Murphy, M. P.; Smith, R. A. Drug delivery to mitochondria: the key to mitochondrial medicine. Adv. Drug Deliv. Rev., 2000, 41, 235-250.
20. Weissig, V.; Boddapati, S. V.; Cheng, S. M.; D'Souza, G. G. Liposomes and liposome-like vesicles for drug and DNA delivery to mitochondria. J. Liposome Res., 2006, 16, 249-264.
21. Torchilin, V. P. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng., 2006, 8, 343-375.
22. Murphy, M. P.; Smith, R. A. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 629-656.
23. Yamada, Y.; Akita, H.; Kogure, K.; Kamiya, H.; Harashima, H. Mitochondrial drug delivery and mitochondrial disease therapy--an approach to liposome-based delivery targeted to mitochondria. Mitochondrion, 2007, 7, 63-71.
24. Kunji, E. R.; Robinson, A. J. The conserved substrate binding site of mitochondrial carriers. Biochim. Biophys. Acta, 2006, 1757, 1237-1248.
25. Sugden, M. C.; Holness, M. J. Interactive regulation of the pyruvate dehydrogenase complex and the carnitine palmitoyltransferase system. FASEB J., 1994, 8, 54-61.
26. Schofield, P. S.; Kerbey, A. L.; Sugden, M. C. Hepatic pyruvate metabolism during liver regeneration after partial hepatectomy in the rat. Int. J. Biochem., 1986, 18, 453-458.
27. Lieber, C. S. New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. Curr. Gastroenterol. Rep., 2004, 6, 60-65.
28. Surh, C. D.; Ahmed-Ansari, A.; Gershwin, M. E. Comparative epitope mapping of murine monoclonal and human autoantibodies to human PDH-E2, the major mitochondrial autoantigen of primary biliary cirrhosis. J. Immunol., 1990, 144, 2647-2652.
29. Surh, C. D.; Coppel, R.; Gershwin, M. E. Structural requirement for autoreactivity on human pyruvate dehydrogenase-E2, the major autoantigen of primary biliary cirrhosis. Implication for a conformational autoepitope. J. Immunol., 1990, 144, 3367-3374.
30. Eaton, S. Control of mitochondrial beta-oxidation flux. Prog. Lipid Res., 2002, 41, 197-239.
31. Serviddio, G.; Bellanti, F.; Tamborra, R.; Rollo, T.; Romano, A. D.; Giudetti, A. M.; Capitanio, N.; Petrella, A.; Vendemiale, G.; Altomare, E. Alterations of hepatic ATP homeostasis and respiratory chain during development of non-alcoholic steatohepatitis in a rodent model. Eur. J. Clin. Invest., 2008, 38, 245-252.
32. Nakamuta, M.; Kohjima, M.; Morizono, S.; Kotoh, K.; Yoshimoto, T.; Miyagi, I.; Enjoji, M. Evaluation of fatty acid metabolismrelated gene expression in nonalcoholic fatty liver disease. Int. J. Mol. Med., 2005, 16, 631-635.
33. Nakamuta, M.; Kohjima, M.; Higuchi, N.; Kato, M.; Kotoh, K.; Yoshimoto, T.; Yada, M.; Yada, R.; Takemoto, R.; Fukuizumi, K.; Harada, N.; Taketomi, A.; Maehara, Y.; Nakashima, M.; Enjoji, M. The significance of differences in fatty acid metabolism between obese and non-obese patients with non-alcoholic fatty liver disease. Int. J. Mol. Med., 2008, 22, 663-667.
34. Fromenty, B.; Pessayre, D. Inhibition of mitochondrial betaoxidation as a mechanism of hepatotoxicity. Pharmacol. Ther., 1995, 67, 101-154.
35. Sheikh, M. Y.; Choi, J.; Qadri, I.; Friedman, J. E.; Sanyal, A. J. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology, 2008, 47, 2127-2133.
36. Purohit, V.; Gao, B.; Song, B. J. Molecular mechanisms of alcoholic fatty liver. Alcohol Clin. Exp. Res., 2009, 33, 191-205.
37. Lang, C.; Berardi, S.; Schafer, M.; Serra, D.; Hegardt, F. G.; Krahenbuhl, L.; Krahenbuhl, S. Impaired ketogenesis is a major mechanism for disturbed hepatic fatty acid metabolism in rats with long-term cholestasis and after relief of biliary obstruction. J. Hepatol., 2002, 37, 564-571.
38. Carini, R.; Comoglio, A.; Albano, E.; Poli, G. Lipid peroxidation and irreversible damage in the rat hepatocyte model. Protection by the silybin-phospholipid complex IdB 1016. Biochem. Pharmacol., 1992, 43, 2111-2115.
39. Nicholls G. C.; Ferguson S. J. Bioenergetics: An Introduction to the Chemiosmotic Theory. 1992.
40. Zhivotovsky, B.; Galluzzi, L.; Kepp, O.; Kroemer, G. Adenine nucleotide translocase: a component of the phylogenetically conserved cell death machinery. Cell Death Differ., 2009, 16, 1419-1425.
41. Burcham, P. C.; Harman, A. W. Acetaminophen toxicity results in site-specific mitochondrial damage in isolated mouse hepatocytes. J. Biol. Chem., 1991, 266, 5049-5054.
42. Nazareth, W. M.; Sethi, J. K.; McLean, A. E. Effect of paracetamol on mitochondrial membrane function in rat liver slices. Biochem. Pharmacol., 1991, 42, 931-936.
43. O'Connor, N.; Dargan, P. I.; Jones, A. L. Hepatocellular damage from non-steroidal anti-inflammatory drugs. QJM, 2003, 96, 787-791.
44. Hartig, S.; Fries, S.; Balcarcel, R. R. Reduced mitochondrial membrane potential and metabolism correspond to acute chloroform toxicity of in vitro hepatocytes. J. Appl. Toxicol., 2005, 25, 310-317.
45. Yamamoto, H.; Watanabe, T.; Mizuno, H.; Endo, K.; Hosokawa, T.; Kazusaka, A.; Gooneratne, R.; Fujita, S. In vivo evidence for accelerated generation of hydroxyl radicals in liver of Long-Evans Cinnamon (LEC) rats with acute hepatitis. Free Radic. Biol. Med., 2001, 30, 547-554.
46. Pardo Andreu, G. L.; Inada, N. M.; Vercesi, A. E.; Curti, C. Uncoupling and oxidative stress in liver mitochondria isolated from rats with acute iron overload. Arch. Toxicol., 2009, 83, 47-53.
47. Crouser, E. D.; Julian, M. W.; Blaho, D. V.; Pfeiffer, D. R. Endotoxin-induced mitochondrial damage correlates with impaired respiratory activity. Crit. Care Med., 2002, 30, 276-284.
48. Crouser, E. D.; Julian, M. W.; Huff, J. E.; Joshi, M. S.; Bauer, J. A.; Gadd, M. E.; Wewers, M. D.; Pfeiffer, D. R. Abnormal permeability of inner and outer mitochondrial membranes contributes independently to mitochondrial dysfunction in the liver during acute endotoxemia. Crit. Care Med., 2004, 32, 478-488.
49. Huet, P. M.; Nagaoka, M. R.; Desbiens, G.; Tarrab, E.; Brault, A.; Bralet, M. P.; Bilodeau, M. Sinusoidal endothelial cell and hepatocyte death following cold ischemia-warm reperfusion of the rat liver. Hepatology, 2004, 39, 1110-1119.
50. Bailey, S. M.; Cunningham, C. C. Contribution of mitochondria to oxidative stress associated with alcoholic liver disease. Free Radic. Biol. Med., 2002, 32, 11-16.
51. Cortez-Pinto, H.; Chatham, J.; Chacko, V. P.; Arnold, C.; Rashid, A.; Diehl, A. M. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA, 1999, 282, 1659-1664.
52. Perez-Carreras, M.; Del Hoyo, P.; Martin, M. A.; Rubio, J. C.; Martin, A.; Castellano, G.; Colina, F.; Arenas, J.; Solis-Herruzo, J. A. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology, 2003, 38, 999-1007.
53. Piccoli, C.; Quarato, G.; Ripoli, M.; D'Aprile, A.; Scrima, R.; Cela, O.; Boffoli, D.; Moradpour, D.; Capitanio, N. HCV infection induces mitochondrial bioenergetic unbalance: causes and effects. Biochim. Biophys. Acta, 2009, 1787, 539-546.
54. Piccoli, C.; Scrima, R.; Quarato, G.; D'Aprile, A.; Ripoli, M.; Lecce, L.; Boffoli, D.; Moradpour, D.; Capitanio, N. Hepatitis C virus protein expression causes calcium-mediated mitochondrial bioenergetic dysfunction and nitro-oxidative stress. Hepatology, 2007, 46, 58-65.
55. Brookes, P. S.; Yoon, Y.; Robotham, J. L.; Anders, M. W.; Sheu, S. S. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am. J. Physiol. Cell Physiol., 2004, 287, C817-C833.
56. Huh, K. W.; Siddiqui, A. Characterization of the mitochondrial association of hepatitis B virus X protein, HBx. Mitochondrion, 2002, 1, 349-359.
57. Clippinger, A. J.; Bouchard, M. J. Hepatitis B virus HBx protein localizes to mitochondria in primary rat hepatocytes and modulates mitochondrial membrane potential. J. Virol., 2008, 82, 6798-6811.
58. Sokol, R. J.; McKim, J. M., Jr.; Goff, M. C.; Ruyle, S. Z.; Devereaux, M. W.; Han, D.; Packer, L.; Everson, G. Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat. Gastroenterology, 1998, 114, 164-174.
59. Chance, B.; Sies, H.; Boveris, A. Hydroperoxide metabolism in mammalian organs. Physiol. Rev., 1979, 59, 527-605.
60. Lenaz, G. The mitochondrial production of reactive oxygen species: mechanism and implications in human pathology. IUBMB Life, 2001, 52, 159-164.
61. Loschen, G.; Azzi, A.; Richter, C.; Flohe, L. Superoxide radicals as precursors of mitochondrial hydrogen peroxide. FEBS Lett., 1974, 42, 68-72.
62. St Pierre, J.; Buckingham, J. A.; Roebuck, S. J.; Brand, M. D. Topology of superoxide production from different sites in the mitochondrial electron transport chain. J. Biol. Chem., 2002, 277, 44784-44790.
63. Skulachev, V. P. Uncoupling: new approaches to an old problem of bioenergetics. Biochim. Biophys. Acta, 1998, 1363, 100-124.
64. Forman, H. J.; Torres, M.; Fukuto, J. Redox signaling. Mol. Cell Biochem., 2002, 234-235, 49-62.
65. Echtay, K. S.; Esteves, T. C.; Pakay, J. L.; Jekabsons, M. B.; Lambert, A. J.; Portero-Otin, M.; Pamplona, R.; Vidal-Puig, A. J.; Wang, S.; Roebuck, S. J.; Brand, M. D. A signalling role for 4-hydroxy-2-nonenal in regulation of mitochondrial uncoupling. EMBO J., 2003, 22, 4103-4110.
66. Poli, G.; Schaur, R. J. 4-Hydroxynonenal in the pathomechanisms of oxidative stress. IUBMB Life, 2000, 50, 315-321.
67. Mari, M.; Colell, A.; Morales, A.; von, M. C.; Garcia-Ruiz, C.; Fernandez-Checa, J. C. Redox control of liver function in health and disease. Antioxid. Redox. Signal., 2010, [Epub ahead of print].
68. Okuda, M.; Lee, H. C.; Kumar, C.; Chance, B. Comparison of the effect of a mitochondrial uncoupler, 2,4-dinitrophenol and adrenaline on oxygen radical production in the isolated perfused rat liver. Acta Physiol. Scand., 1992, 145, 159-168.
69. Korshunov, S. S.; Skulachev, V. P.; Starkov, A. A. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett., 1997, 416, 15-18.
70. Miwa, S.; St Pierre, J.; Partridge, L.; Brand, M. D. Superoxide and hydrogen peroxide production by Drosophila mitochondria. Free Radic. Biol. Med., 2003, 35, 938-948.
71. James, L. P.; Mayeux, P. R.; Hinson, J. A. Acetaminophen-induced hepatotoxicity. Drug Metab. Dispos., 2003, 31, 1499-1506.
72. Kebieche, M.; Lakroun, Z.; Lahouel, M.; Bouayed, J.; Meraihi, Z.; Soulimani, R. Evaluation of epirubicin-induced acute oxidative stress toxicity in rat liver cells and mitochondria, and the prevention of toxicity through quercetin administration. Exp. Toxicol. Pathol., 2009, 61, 161-167.
73. Glantzounis, G. K.; Salacinski, H. J.; Yang, W.; Davidson, B. R.; Seifalian, A. M. The contemporary role of antioxidant therapy in attenuating liver ischemia-reperfusion injury: a review. Liver Transpl., 2005, 11, 1031-1047.
74. Bailey, S. M. A review of the role of reactive oxygen and nitrogen species in alcohol-induced mitochondrial dysfunction. Free Radic. Res., 2003, 37, 585-596.
75. Minana, J. B.; Gomez-Cambronero, L.; Lloret, A.; Pallardo, F. V.; Del Olmo, J.; Escudero, A.; Rodrigo, J. M.; Pelliin, A.; Vina, J. R.; Vina, J.; Sastre, J. Mitochondrial oxidative stress and CD95 ligand: a dual mechanism for hepatocyte apoptosis in chronic alcoholism. Hepatology, 2002, 35, 1205-1214.
76. Serviddio, G.; Pereda, J.; Pallardo, F. V.; Carretero, J.; Borras, C.; Cutrin, J.; Vendemiale, G.; Poli, G.; Vina, J.; Sastre, J. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology, 2004, 39, 711-720.
77. Serviddio, G.; Sastre, J. Measurement of mitochondrial membrane potential and proton leak. Methods Mol. Biol., 2010, 594, 107-121.
78. Terada, H. Uncouplers of oxidative phosphorylation. Environ. Health Perspect., 1990, 87, 213-218.
79. Heytler, P. G. Uncouplers of oxidative phosphorylation. Pharmacol. Ther., 1980, 10, 461-472.
80. Kohnke, D.; Ludwig, B.; Kadenbach, B. A threshold membrane potential accounts for controversial effects of fatty acids on mitochondrial oxidative phosphorylation. FEBS Lett., 1993, 336, 90-94.
81. Boss, O.; Muzzin, P.; Giacobino, J. P. The uncoupling proteins, a review. Eur. J. Endocrinol., 1998, 139, 1-9.
82. Kadenbach, B. Intrinsic and extrinsic uncoupling of oxidative phosphorylation. Biochim. Biophys. Acta, 2003, 1604, 77-94.
83. Larrouy, D.; Laharrague, P.; Carrera, G.; Viguerie-Bascands, N.; Levi-Meyrueis, C.; Fleury, C.; Pecqueur, C.; Nibbelink, M.; Andre, M.; Casteilla, L.; Ricquier, D. Kupffer cells are a dominant site of uncoupling protein 2 expression in rat liver. Biochem. Biophys. Res. Commun., 1997, 235, 760-764.
84. Chavin, K. D.; Yang, S.; Lin, H. Z.; Chatham, J.; Chacko, V. P.; Hoek, J. B.; Walajtys-Rode, E.; Rashid, A.; Chen, C. H.; Huang, C. C.; Wu, T. C.; Lane, M. D.; Diehl, A. M. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J. Biol. Chem., 1999, 274, 5692-5700.
85. Rashid, A.; Wu, T. C.; Huang, C. C.; Chen, C. H.; Lin, H. Z.; Yang, S. Q.; Lee, F. Y.; Diehl, A. M. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. Hepatology, 1999, 29, 1131-1138.
86. Negre-Salvayre, A.; Hirtz, C.; Carrera, G.; Cazenave, R.; Troly, M.; Salvayre, R.; Penicaud, L.; Casteilla, L. A role for uncoupling protein-2 as a regulator of mitochondrial hydrogen peroxide generation. FASEB J., 1997, 11, 809-815.
87. Green, D. R.; Reed, J. C. Mitochondria and apoptosis. Science, 1998, 281, 1309-1312.
88. Smith, D. J.; Ng, H.; Kluck, R. M.; Nagley, P. The mitochondrial gateway to cell death. IUBMB Life, 2008, 60, 383-389.
89. Jeong, S. Y.; Seol, D. W. The role of mitochondria in apoptosis. BMB Rep., 2008, 41, 11-22.
90. Harris, M. H.; Thompson, C. B. The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ., 2000, 7, 1182-1191.
91. Cesura, A. M.; Pinard, E.; Schubenel, R.; Goetschy, V.; Friedlein, A.; Langen, H.; Polcic, P.; Forte, M. A.; Bernardi, P.; Kemp, J. A. The voltage-dependent anion channel is the target for a new class of inhibitors of the mitochondrial permeability transition pore. J. Biol. Chem., 2003, 278, 49812-49818.
92. Rasola, A.; Bernardi, P. The mitochondrial permeability transition pore and its involvement in cell death and in disease pathogenesis. Apoptosis, 2007, 12, 815-833.
93. Goldman, S. J.; Taylor, R.; Zhang, Y.; Jin, S. Autophagy and the degradation of mitochondria. Mitochondrion, 2010, [Epub ahead of print].
94. Baines, C. P.; Kaiser, R. A.; Purcell, N. H.; Blair, N. S.; Osinska, H.; Hambleton, M. A.; Brunskill, E. W.; Sayen, M. R.; Gottlieb, R. A.; Dorn, G. W.; Robbins, J.; Molkentin, J. D. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature, 2005, 434, 658-662.
95. Griffin, E. E.; Chan, D. C. Domain interactions within Fzo1 oligomers are essential for mitochondrial fusion. J. Biol. Chem., 2006, 281, 16599-16606.
96. Jagasia, R.; Grote, P.; Westermann, B.; Conradt, B. DRP-1-mediated mitochondrial fragmentation during EGL-1-induced cell death in C. elegans. Nature, 2005, 433, 754-760.
97. Youle, R. J.; Karbowski, M. Mitochondrial fission in apoptosis. Nat. Rev. Mol. Cell Biol., 2005, 6, 657-663.
98. Baffy, G. Uncoupling protein-2 and non-alcoholic fatty liver disease. Front Biosci., 2005, 10, 2082-2096.
99. Joshi, B.; Li, L.; Taffe, B. G.; Zhu, Z.; Wahl, S.; Tian, H.; Ben- Josef, E.; Taylor, J. D.; Porter, A. T.; Tang, D. G. Apoptosis induction by a novel anti-prostate cancer compound, BMD188 (a fatty acid-containing hydroxamic acid), requires the mitochondrial respiratory chain. Cancer Res., 1999, 59, 4343-4355.
100. Matsuyama, S.; Llopis, J.; Deveraux, Q. L.; Tsien, R. Y.; Reed, J. C. Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis. Nat. Cell Biol., 2000, 2, 318-325.
101. Masubuchi, Y.; Suda, C.; Horie, T. Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice. J. Hepatol., 2005, 42, 110-116.
102. Kim, J. S.; He, L.; Qian, T.; Lemasters, J. J. Role of the mitochondrial permeability transition in apoptotic and necrotic death after ischemia/reperfusion injury to hepatocytes. Curr. Mol. Med., 2003, 3, 527-535.
103. Yan, M.; Zhu, P.; Liu, H. M.; Zhang, H. T.; Liu, L. Ethanol induced mitochondria injury and permeability transition pore opening: role of mitochondria in alcoholic liver disease. World J. Gastroenterol., 2007, 13, 2352-2356.
104. Serviddio, G.; Bellanti, F.; Tamborra, R.; Rollo, T.; Capitanio, N.; Romano, A. D.; Sastre, J.; Vendemiale, G.; Altomare, E. Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia-reperfusion injury. Gut, 2008, 57, 957-965.
105. Tan, C.; Guo, H.; Zheng, M.; Chen, Y.; Huang, W. Involvement of mitochondrial permeability transition in hepatitis B virus replication. Virus Res., 2009, 145, 307-311.
106. Botla, R.; Spivey, J. R.; Aguilar, H.; Bronk, S. F.; Gores, G. J. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection. J. Pharmacol. Exp. Ther., 1995, 272, 930-938.
107. Taniguchi, E.; Harada, M.; Kawaguchi, T.; Koga, H.; Kumemura, H.; Hanada, S.; Shishido, S.; Baba, S.; Kumashiro, R.; Ueno, T.; Sakisaka, S.; Sata, M. Expression of uncoupling protein-2 in biliary epithelial cells in primary biliary cirrhosis. Liver, 2002, 22, 451-458.
108. Wu, J.; Nantz, M. H.; Zern, M. A. Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications. Front Biosci., 2002, 7, d717-d725.
109. Beljaars, L.; Molema, G.; Weert, B.; Bonnema, H.; Olinga, P.; Groothuis, G. M.; Meijer, D. K.; Poelstra, K. Albumin modified with mannose 6-phosphate: A potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells. Hepatology, 1999, 29, 1486-1493.
110. Murphy, M. P. Selective targeting of bioactive compounds to mitochondria. Trends Biotechnol., 1997, 15, 326-330.
111. Yousif, L. F.; Stewart, K. M.; Kelley, S. O. Targeting mitochondria with organelle-specific compounds: strategies and applications. Chembiochem, 2009, 10, 1939-1950.
112. Yousif, L. F.; Stewart, K. M.; Horton, K. L.; Kelley, S. O. Mitochondria-penetrating peptides: sequence effects and model cargo transport. Chembiochem, 2009, 10, 2081-2088.
113. Domenicali, M.; Caraceni, P.; Vendemiale, G.; Grattagliano, I.; Nardo, B.; Dall'Agata, M.; Santoni, B.; Trevisani, F.; Cavallari, A.; Altomare, E.; Bernardi, M. Food deprivation exacerbates mitochondrial oxidative stress in rat liver exposed to ischemiareperfusion injury. J. Nutr., 2001, 131, 105-110.
114. Breunig, M.; Bauer, S.; Goepferich, A. Polymers and nanoparticles: intelligent tools for intracellular targeting? Eur. J. Pharm. Biopharm., 2008, 68, 112-128.
115. Nishikawa, Y.; Takahashi, M.; Yorifuji, S.; Nakamura, Y.; Ueno, S.; Tarui, S.; Kozuka, T.; Nishimura, T. Long-term coenzyme Q10 therapy for a mitochondrial encephalomyopathy with cytochrome c oxidase deficiency: a 31P NMR study. Neurology, 1989, 39, 399-403.
116. Suzuki, Y.; Kadowaki, H.; Atsumi, Y.; Hosokawa, K.; Katagiri, H.; Kadowaki, T.; Oka, Y.; Uyama, K.; Mokubo, A.; Asahina, T.;. A case of diabetic amyotrophy associated with 3243 mitochondrial tRNA(leu; UUR) mutation and successful therapy with coenzyme Q10. Endocr. J., 1995, 42, 141-145.
117. Tanaka, J.; Nagai, T.; Arai, H.; Inui, K.; Yamanouchi, H.; Goto, Y.; Nonaka, I.; Okada, S. Treatment of mitochondrial encephalomyopathy with a combination of cytochrome C and vitamins B1 and B2. Brain Dev., 1997, 19, 262-267.
118. van Delft, M. F.; Wei, A. H.; Mason, K. D.; Vandenberg, C. J.; Chen, L.; Czabotar, P. E.; Willis, S. N.; Scott, C. L.; Day, C. L.; Cory, S.; Adams, J. M.; Roberts, A. W.; Huang, D. C. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell, 2006, 10, 389-399.
119. Deng, J.; Dayam, R.; Neamati, N. Patented small molecule inhibitors of p53-MDM2 interaction. Expert Opin. Ther. Pat., 2006, 16, 165-188.
120. Yokoyama, M. Drug targeting with nano-sized carrier systems. J. Artif. Organs, 2005, 8, 77-84.
121. Smith, R. A.; Porteous, C. M.; Coulter, C. V.; Murphy, M. P. Selective targeting of an antioxidant to mitochondria. Eur. J. Biochem., 1999, 263, 709-716.
122. James, A. M.; Cocheme, H. M.; Smith, R. A.; Murphy, M. P. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools. J. Biol. Chem., 2005, 280, 21295-21312.
123. James, A. M.; Sharpley, M. S.; Manas, A. R.; Frerman, F. E.; Hirst, J.; Smith, R. A.; Murphy, M. P. Interaction of the mitochondriatargeted antioxidant MitoQ with phospholipid bilayers and ubiquinone oxidoreductases. J. Biol. Chem., 2007, 282, 14708-14718.
124. Muratovska, A.; Lightowlers, R. N.; Taylor, R. W.; Turnbull, D. M.; Smith, R. A.; Wilce, J. A.; Martin, S. W.; Murphy, M. P. Targeting peptide nucleic acid (PNA) oligomers to mitochondria within cells by conjugation to lipophilic cations: implications for mitochondrial DNA replication, expression and disease. Nucleic Acids Res., 2001, 29, 1852-1863.
125. Filipovska, A.; Kelso, G. F.; Brown, S. E.; Beer, S. M.; Smith, R. A.; Murphy, M. P. Synthesis and characterization of a triphenylphosphonium-conjugated peroxidase mimetic. Insights into the interaction of ebselen with mitochondria. J. Biol. Chem., 2005, 280, 24113-24126.
126. Sheu, S. S.; Nauduri, D.; Anders, M. W. Targeting antioxidants to mitochondria: a new therapeutic direction. Biochim. Biophys. Acta, 2006, 1762, 256-265.
127. Trnka, J.; Blaikie, F. H.; Smith, R. A.; Murphy, M. P. A mitochondria-targeted nitroxide is reduced to its hydroxylamine by ubiquinol in mitochondria. Free Radic. Biol. Med., 2008, 44, 1406-1419.
128. Lowes, D. A.; Thottakam, B. M.; Webster, N. R.; Murphy, M. P.; Galley, H. F. The mitochondria-targeted antioxidant MitoQ protects against organ damage in a lipopolysaccharidepeptidoglycan model of sepsis. Free Radic. Biol. Med., 2008, 45, 1559-1565.
129. Whiteman, M.; Spencer, J. P.; Szeto, H. H.; Armstrong, J. S. Do mitochondriotropic antioxidants prevent chlorinative stress-induced mitochondrial and cellular injury? Antioxid. Redox. Signal., 2008, 10, 641-650.
130. Biasutto, L.; Mattarei, A.; Marotta, E.; Bradaschia, A.; Sassi, N.; Garbisa, S.; Zoratti, M.; Paradisi, C. Development of mitochondriatargeted derivatives of resveratrol. Bioorg. Med. Chem. Lett., 2008, 18, 5594-5597.
131. Blaikie, F. H.; Brown, S. E.; Samuelsson, L. M.; Brand, M. D.; Smith, R. A.; Murphy, M. P. Targeting dinitrophenol to mitochondria: limitations to the development of a self-limiting mitochondrial protonophore. Biosci. Rep., 2006, 26, 231-243.
132. Weissig, V. Mitochondrial-targeted drug and DNA delivery. Crit. Rev. Ther. Drug Carrier Syst., 2003, 20, 1-62.
133. Murphy, M. P. Targeting lipophilic cations to mitochondria. Biochim. Biophys. Acta, 2008, 1777, 1028-1031.
134. Demeilliers, C.; Maisonneuve, C.; Grodet, A.; Mansouri, A.; Nguyen, R.; Tinel, M.; Letteron, P.; Degott, C.; Feldmann, G.; Pessayre, D.; Fromenty, B. Impaired adaptive resynthesis and prolonged depletion of hepatic mitochondrial DNA after repeated alcohol binges in mice. Gastroenterology, 2002, 123, 1278-1290.
135. Ducluzeau, P. H.; Lachaux, A.; Bouvier, R.; Streichenberger, N.; Stepien, G.; Mousson, B. Depletion of mitochondrial DNA associated with infantile cholestasis and progressive liver fibrosis. J. Hepatol., 1999, 30, 149-155.
136. Nishikawa, M.; Nishiguchi, S.; Kioka, K.; Tamori, A.; Inoue, M. Interferon reduces somatic mutation of mitochondrial DNA in liver tissues from chronic viral hepatitis patients. J. Viral Hepat., 2005, 12, 494-498.
137. Kawahara, H.; Fukura, M.; Tsuchishima, M.; Takase, S. Mutation of mitochondrial DNA in livers from patients with alcoholic hepatitis and nonalcoholic steatohepatitis. Alcohol Clin. Exp. Res., 2007, 31, S54-S60.
138. Szeto, H. H. Mitochondria-targeted peptide antioxidants: novel neuroprotective agents. AAPS J., 2006, 8, E521-E531.
139. Szeto, H. H. Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS J., 2006, 8, E277-E283.
140. Zhao, K.; Zhao, G. M.; Wu, D.; Soong, Y.; Birk, A. V.; Schiller, P. W.; Szeto, H. H. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J. Biol. Chem., 2004, 279, 34682-34690.
141. Yamada, Y.; Harashima, H. Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases. Adv. Drug Deliv. Rev., 2008, 60, 1439-1462.
142. Szeto, H. H. Development of mitochondria-targeted aromaticcationic peptides for neurodegenerative diseases. Ann. N. Y. Acad. Sci., 2008, 1147, 112-121.
143. Stone, W. L.; Smith, M. Therapeutic uses of antioxidant liposomes. Mol. Biotechnol., 2004, 27, 217-230.
144. Hillaireau, H.; Couvreur, P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol. Life Sci., 2009, 66, 2873-2896.
145. Slepushkin, V. A.; Simoes, S.; Dazin, P.; Newman, M. S.; Guo, L. S.; Pedroso de Lima, M. C.; Duzgunes, N. Sterically stabilized pHsensitive liposomes. Intracellular delivery of aqueous contents and prolonged circulation in vivo. J. Biol. Chem., 1997, 272, 2382-2388.
146. Alipour, M.; Omri, A.; Smith, M. G.; Suntres, Z. E. Prophylactic effect of liposomal N-acetylcysteine against LPS-induced liver injuries. J. Endotoxin. Res., 2007, 13, 297-304.
147. Di Sario, A.; Bendia, E.; Taffetani, S.; Omenetti, A.; Candelaresi, C.; Marzioni, M.; De Minicis, S.; Benedetti, A. Hepatoprotective and antifibrotic effect of a new silybin-phosphatidylcholine- Vitamin E complex in rats. Dig. Liver Dis., 2005, 37, 869-876.
148. Loguercio, C.; Federico, A.; Trappoliere, M.; Tuccillo, C.; Sio, I.; Leva, A. D.; Niosi, M.; D'Auria, M. V.; Capasso, R.; Blanco, C., V The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic Fatty liver disease: a pilot study. Dig. Dis. Sci., 2007, 52, 2387-2395.
149. Serviddio, G.; Bellanti, F.; Giudetti, A. M.; Gnoni, G. V.; Petrella, A.; Tamborra, R.; Romano, A. D.; Rollo, T.; Vendemiale, G.; Altomare, E. A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis. J. Pharmacol. Exp. Ther., 2010, 332, 922-932.
150. Mandal, A. K.; Das, S.; Basu, M. K.; Chakrabarti, R. N.; Das, N. Hepatoprotective activity of liposomal flavonoid against arseniteinduced liver fibrosis. J. Pharmacol. Exp. Ther., 2007, 320, 994-1001.
151. Mandal, A. K.; Das, S.; Mitra, M.; Chakrabarti, R. N.; Chatterjee, M.; Das, N. Vesicular flavonoid in combating diethylnitrosamine induced hepatocarcinoma in rat model. J. Exp. Ther. Oncol., 2008, 7, 123-133.
152. Korb, V.; Tep, K.; Escriou, V.; Richard, C.; Scherman, D.; Cynober, L.; Chaumeil, J.; Dumortier, G. Current data on ATPcontaining liposomes and potential prospects to enhance cellular energy status for hepatic applications. Crit. Rev. Ther. Drug Carrier Syst., 2008, 25, 305-345.
153. Fittipaldi, A.; Giacca, M. Transcellular protein transduction using the Tat protein of HIV-1. Adv. Drug Deliv. Rev., 2005, 57, 597-608.
154. Torchilin, V. P.; Rammohan, R.; Weissig, V.; Levchenko, T. S. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. Natl. Acad. Sci. U.S.A., 2001, 98, 8786-8791.
155. Joliot, A.; Prochiantz, A. Transduction peptides: from technology to physiology. Nat. Cell Biol., 2004, 6, 189-196.
156. Del, G., V; MacKenzie, J. A.; Payne, R. M. Targeting proteins to mitochondria using TAT. Mol. Genet. Metab, 2003, 80, 170-180.
157. Doh, K. O.; Jung, H. K.; Moon, I. J.; Kang, H. G.; Park, J. H.; Park, J. G. Prevention of CCl4-induced liver cirrhosis by ribbon antisense to transforming growth factor-beta1. Int. J. Mol. Med., 2008, 21, 33-39.
158. Kellermann, G.; Boudechiche, L.; Weber, A.; Hadchouel, M. Increased engraftment of hepatic progenitors after activation of the hepatocyte growth factor signaling pathway by protein transduction. Exp. Biol. Med. (Maywood.), 2009, 234, 1102-1108.
159. Wei, B.; Wei, Y.; Zhang, K.; Wang, J.; Xu, R.; Zhan, S.; Lin, G.; Wang, W.; Liu, M.; Wang, L.; Zhang, R.; Li, J. Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell-penetrating peptide. Biomed. Pharmacother., 2009, 63, 313-318.
160. Asayama, S.; Kawamura, E.; Nagaoka, S.; Kawakami, H. Design of manganese porphyrin modified with mitochondrial signal peptide for a new antioxidant. Mol. Pharm., 2006, 3, 468-470.
161. Trnka, J.; Blaikie, F. H.; Logan, A.; Smith, R. A.; Murphy, M. P. Antioxidant properties of MitoTEMPOL and its hydroxylamine. Free Radic. Res., 2009, 43, 4-12.
162. Chacinska, A.; Koehler, C. M.; Milenkovic, D.; Lithgow, T.; Pfanner, N. Importing mitochondrial proteins: machineries and mechanisms. Cell, 2009, 138, 628-644.
163. Dolezal, P.; Likic, V.; Tachezy, J.; Lithgow, T. Evolution of the molecular machines for protein import into mitochondria. Science, 2006, 313, 314-318.
164. Wickner, W.; Schekman, R. Protein translocation across biological membranes. Science, 2005, 310, 1452-1456.
165. Milenkovic, D.; Muller, J.; Stojanovski, D.; Pfanner, N.; Chacinska, A. Diverse mechanisms and machineries for import of mitochondrial proteins. Biol. Chem., 2007, 388, 891-897.
166. Bohnert, M.; Pfanner, N.; van der Laan, M. A dynamic machinery for import of mitochondrial precursor proteins. FEBS Lett., 2007, 581, 2802-2810.
167. Endo, T.; Yamano, K. Multiple pathways for mitochondrial protein traffic. Biol. Chem., 2009, 390, 723-730.
168. Manfredi, G.; Fu, J.; Ojaimi, J.; Sadlock, J. E.; Kwong, J. Q.; Guy, J.; Schon, E. A. Rescue of a deficiency in ATP synthesis by transfer of MTATP6, a mitochondrial DNA-encoded gene, to the nucleus. Nat. Genet., 2002, 30, 394-399.
169. Zullo, S. J.; Parks, W. T.; Chloupkova, M.; Wei, B.; Weiner, H.; Fenton, W. A.; Eisenstadt, J. M.; Merril, C. R. Stable transformation of CHO Cells and human NARP cybrids confers oligomycin resistance (oli(r)) following transfer of a mitochondrial DNA-encoded oli(r) ATPase6 gene to the nuclear genome: a model system for mtDNA gene therapy. Rejuvenation Res., 2005, 8, 18-28.
170. Fink, M. P.; Macias, C. A.; Xiao, J.; Tyurina, Y. Y.; Jiang, J.; Belikova, N.; Delude, R. L.; Greenberger, J. S.; Kagan, V. E.; Wipf, P. Hemigramicidin-TEMPO conjugates: novel mitochondriatargeted anti-oxidants. Biochem. Pharmacol., 2007, 74, 801-809.
171. Macias, C. A.; Chiao, J. W.; Xiao, J.; Arora, D. S.; Tyurina, Y. Y.; Delude, R. L.; Wipf, P.; Kagan, V. E.; Fink, M. P. Treatment with a novel hemigramicidin-TEMPO conjugate prolongs survival in a rat model of lethal hemorrhagic shock. Ann. Surg., 2007, 245, 305-314.
172. Kogure, K.; Akita, H.; Yamada, Y.; Harashima, H. Multifunctional envelope-type nano device (MEND) as a non-viral gene delivery system. Adv. Drug Deliv. Rev., 2008, 60, 559-571.